Omnigen in Acute Chemical Eye Injuries

Not Applicable

Completed

• Conditions: Acute Chemical Eye Injuries

• Registration Number: NCT05618522
• Lead Sponsor: Farwaniya Hospital

Brief Summary

evaluation of the role of Omnigen in acute chemical eye injuries

Detailed Description

prospective interventional study included patients with different degrees of acute chemical eye injuries were treated by Omnigen and followed up for one month

Study Timeline

• Study Start: 2021-07-01
• Primary Completion: 2022-07-01
• Study Completion: 2022-09-01
• Status Verified: 2022-11
• Study First Submitted: 2022-11-09
• Study First Submitted QC: 2022-11-15
• Last Update Submitted: 2022-11-15
• Study First Posted: 2022-11-16
• Last Update Posted: 2022-11-16

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• acute chemical eye injury

Exclusion Criteria

• absent or shallow fornices
• symblepharon interfering with lens placement

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Epithelial healing	1 week	slit lamp examination with cobalt blue light after installing fluroscein drops
limbal ischaemia	1 week	slit lamp examination of the clock hours of vascularity around the limbususing both Due classification and Roper Hall

Secondary Outcome Measures

Name	Time	Method
omnigen tolerability	1 week	questionnaire for the patients asking about discomfort sensation or the need to patch the eye

Trial Locations

Locations (1)

Farwanyia Hospital; 🇰🇼 Al Farwānīyah, Farwanyia, Kuwait